Vakcīnas patenta relaksācija: World Tourism Network atbalsta ASV soli

Jūsu darbs IR Klientu apkalpošana Veselība bez robežām iniciatīva World Tourism Network (WTN) welcomes this initiative. WTN Chairman Juergen Steinmetz said: “President Biden’s brave move here is the type of leadership I can be proud of as a US and global citizen.”

WTN President Dr. Peter Tarlow yesterday was awarded the United States Public Health Service’s highest Civilian Award for his efforts through the World Tourism Network in the fight against COVID-19.

Glorija Guevara, Pasaules ceļojumu un tūrisma padome (WTTC), said on May 1 that health experts shared their concern if the patent is shared – some low-quality labs might want to produce it with not the proper quality standards. This will negatively impact people.

She added: “We need to ask the owners of the patents to work on a massive distribution program and only share patents with those that will support the strategy and program.

Cuthbert Ncube, Chairman of the African Tourism Board, said: The vaccine is essential for tourism to function in a global interconnected world. I fully agree with President Biden in saying : No one is safe until everyone is safe. The Āfrikas tūrisma padome applauds and supports the Health Without Borders initiative of the World Tourism Network. "

Today, the Biden Administration indicated: The US government supports the demand for a suspension of patent protection for corona vaccines. The US trade representative Tai said in Washington that the US is in favor of protecting intellectual property.

But the pandemic calls for extraordinary measures. Therefore, the US government will work with the World Trade Organization to temporarily lift patent protection to combat COVID-19.

More than 100 member states have already made this request at the WTO.

The aim is for more companies to be able to manufacture corona vaccines.

Important countries of origin of the pharmaceutical industry, however, reject the initiative. The US has also been against it so far.

Through the NIH research institute, Washington owns the rights to an invention that is considered a prerequisite for modern mRNA vaccines from the manufacturers Moderna and Biotech/Pfizer.